KalVista Shares New Data on HAE Pill, Highlighting Early Treatment Results at ACAAI Conference
KalVista Shares New Data on HAE Pill, Highlighting Early Treatment Results at ACAAI Conference
KalVista公司在ACAAI会议上发布HAE药丸的新数据，突出早期治疗结果
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced the presentation of new sebetralstat data at the American College of Allergy Asthma and Immunology (ACAAI) taking place in Boston, MA from October 24 - 28, 2024.
kalvista pharmaceuticals今天宣布，在2024年10月24日至28日期间在美国波士顿举行的美国变态反应哮喘和免疫学学院(ACAAI)上发布了新的sebetralstat数据。
Tim Craig, DO, Professor, Departments of Medicine and Pediatrics, Division of Pulmonary, Allergy and Critical Care Medicine, Penn State Health, and KONFIDENT investigator, presented data on the Correlation of Time to Treatment with Attack Duration in the Sebetralstat KONFIDENT Phase 3 Trial that showed complete attack resolution was achieved faster in attacks that were treated earlier (1st quartile) compared with those treated later (4th quartile).
tim董事，任教于宾夕法尼亚州立大学健康部门的内科和儿科肺部、变态反应和重症医学系，并担任KONFIDENt调查员，在sebetralstat KONFIDENt第3期试验中就治疗时间与发作持续时间的相关性进行了数据展示，结果显示早期治疗(第1四分位数)的发作在达到完全缓解方面比后期治疗(第4四分位数)更快。
"This is the first time in a Phase...
“这是第一次在一...
登录免费看全文
登录/注册
资讯热榜
更新时间